

# GAP Pricing

Gail Stone F.S.A.

Actuarial-DMA

4/14/11

---

---

---

---

---

---

---

---

---

---

Total Cost Impact Effective 1/1/2013			
Benefit	SFY 13	SFY 14	SFY 15
Zostavax	\$1,272,175	1,455,368	\$901,270
HPV	\$3,056,099	\$4,670,199	\$3,219,055
Abdominal Aortic Aneurysm Ultrasound / CT	\$51,704	\$115,311	\$120,299
BRCA1 or BRCA2	\$4,424,536	\$9,387,981	\$9,927,377
Counseling for Obesity*			
Counseling for STI*			
Aspirin to prevent Cardiovascular disease	\$3,291,636	\$7,084,169	\$7,623,870
Folic Acid	\$639,944	\$1,964,430	\$2,768,966
Iron	\$51,826	\$108,051	\$112,637
Breast Feeding Support			
<b>Total</b>	<b>\$12,797,921</b>	<b>\$24,785,508</b>	<b>\$24,673,474</b>

State Cost Impact Effective 1/1/2013			
Benefit	SFY 13	SFY 14	SFY 15
Zostavax	\$436,229	\$499,046	\$309,045
HPV	\$1,047,937	\$1,601,411	\$1,103,814
Abdominal Aortic Aneurysm Ultrasound / CT	\$21,158	\$38,540	\$41,251
BRCA1 or BRCA2	\$1,517,173	\$3,219,139	\$3,404,098
Counseling for Obesity*			
Counseling for STI*			
Aspirin to prevent Cardiovascular disease	\$1,128,702	\$2,429,161	\$2,614,225
Folic Acid	\$219,437	\$673,603	\$949,478
Iron	\$17,771	\$37,051	\$38,623
Breast Feeding Support*			
<b>State Total</b>	<b>\$4,388,407</b>	<b>\$8,498,951</b>	<b>\$8,460,534</b>

\* Already covered as part of office visit

---

---

---

---

---

---

---

---

---

---

Benefits and Areas Where there would be an Additional Financial Impact

Preventive Service Group	Benefit	Population Impacted
Immunization*	Zostavax	60+ non Medicare eligible
Immunization*	HPV	21-26 female
Screening Radiology	Abdominal Aortic Aneurysm Ultrasound / CT	males 65-75 if non Medicare eligible
Genetic Counseling & Testing	BRCA1 or BRCA2	18+ female
Other	Counseling for Obesity	covered as part of office visit
Other	Counseling for STI	covered as part of office visit
Other	Aspirin to prevent Cardiovascular disease	men 45-79 & women 55-79
Other	Folic Acid	Females 18-45
Other	Iron	6-12 months of age
Other	Breast Feeding Support	covered as part of office visit

\* Immunization needs to be part of office visit and therefore no copay applies

---

---

---

---

---

---

---

---

---

---

### Zostavax

- Population is Medicaid eligibles aged 60 and over and not Dually eligible
- 50% of individuals will receive the vaccine each SFY (excluding those who received the vaccine the previous years).
- Population who are non Dually eligible is expected to grow 5.0% year.
- 50% of those receiving the vaccine will receive it alone; 50% will receive it in combination with another vaccine
- Cost of vaccine will increase 4% per year.
- Effective date is 1/1/13
- Base SFY 2010 eligibles are 21,626
- Base SFY 2010 vaccine + admin cost is \$190.42 or \$185.44 if have 2 vaccines at same time.

---

---

---

---

---

---

---

---

### Gardasil Vaccine (HPV)

- Population is woman aged 21-26 net of Family Planning waiver.
- Population trend decreasing 3% per year for net eligibles.
- Eligibles will elect to receive vaccine will do so only once per lifetime.
- Assumed those who elect vaccine will receive 2 doses.
- Cost of vaccine will increase 4% per year.
- Effective date is 1/1/13
- Projected # eligibles for SFY 2013 is 62,687
- Projected % of women receiving vaccine 30% of those eligible
- Drug + Admin cost for base year SFY 2010 is \$151.43

---

---

---

---

---

---

---

---

### Abdominal Aortic Aneurysm Ultrasound

- Population is male 65-75 Non Dual and 65-75 Dual
- Males 65-75 and not Dual for SFY 2013 projected to be 642
- Males 65-75 and Dual for SFY 2013 projected to be 30,997
- Population trend increasing 3% per year.
- 16% will get procedure in any one year.
- 6.4% will repeat procedure.
- Cost of procedure for Dual eligible is 20% of that of Non Dual.
- Procedure cost for base period \$111
- Effective date is 1/1/13

---

---

---

---

---

---

---

---

### BRCA Testing

- Eligible population is female 18 and above.
- .5% or 3,222 of 644,349 eligibles will receive testing.
- Population trend increasing 3% per year.
- Number of recipients receiving a particular test and associated costs was supplied by our Clinical dept.
- Genetic counseling assumed to be 3 units per tested recipient
- Effective date is 1/1/13

---

---

---

---

---

---

---

---

### Aspirin

- Eligible population are males 45-79 and females 55-79.
- Projected number of eligibles in SFY 2013 is
  - Male 141,790 and Female 138,441
- Assume 50% will use benefit.
- Population trend increasing 4% per year male and 2% female.
- Rx cost trend is 4%.
- Cost of meds is \$3.62 for 30 pills and is base year 2011
- Usage assumed for full year
- Effective date is 1/1/13

---

---

---

---

---

---

---

---

### Folic Acid

- Eligible population are females 18-45.
  - This is projected to be 461,517 in SFY 2013
- Those assumed to use the benefit are 5% of the eligibles or 23,076 in SFY 2013
- Usage will be 5% in SFY 2013 increasing by 2%/ yr
- Population trend increasing 5% per year.
- Rx cost per month is \$6.41 for base year 2011
- Rx used for full 8 months.
- Rx cost trend is 4%.
- Effective date is 1/1/13

---

---

---

---

---

---

---

---

### Iron

- Eligible population are aged 6-12 months of age.
- Projected eligibles for SFY 2013 are 47,505
- Breast fed eligibles are 26.5%
  - 70% try breast feeding with 36% at 6 mo, and 17% at 12 months.
- 75% will use supplement
- Projected benefit users are 9,442 for SFY 2013
- Population trend increasing .2% per year.
- Rx cost trend is 4%.
- Cost of Rx for SFY 2011 is \$10.15 for 50 ml bottle
  - This can last 3 months
- Effective date is 1/1/13

---

---

---

---

---

---

---

---